title: Bupropion in adults with Attention-Deficit/Hyperactivity Disorder: a randomized, double-blind study.
abstract: Attention-Deficit/Hyperactivity Disorder is one of the most common mental disorders in childhood, and it continues to adulthood without proper treatment. Stimulants have been used in the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) for many years, and the efficacy of methylphenidate in the treatment of adults with ADHD has been proven to be acceptable according to meta-analysis studies. However, there are some concerns about stimulants. Finding other effective medications for the treatment of adult ADHD seems necessary. We hypothesized bupropion could be effective in the treatment of adult ADHD because some theoretical and experimental evidence exists to support efficacy of this medication. Forty-two patients with a diagnosis of ADHD, according to the revised fourth edition of the Diagnostic and Statistical Manual of Mental Disorders, were randomized to receive 150 mg/day bupropion or placebo for a 6-week double-blind, placebo-controlled clinical trial. Each patient filled the Conners' Adult ADHD Rating Scales-Self-Report-Screening version (CAARS) before starting to take medication and in weeks 3 and 6 of the study. The mean score of the two groups receiving bupropion or placebo decreased over the 6 weeks. There was a significant difference between the two groups in CAARS score after 6 weeks. Bupropion is more effective than placebo in the treatment of adults with ADHD. Bupropion can be an alternative medication for the treatment of Adults with ADHD as its clinical efficacy was proven by other studies.
authors.affiliation: Psychiatric Research Centre, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran. s.akhond@neda.net.
authors.forename: Mehdi
authors.initials: M
authors.lastname: Hamedi
authors.affiliation: Psychiatric Research Centre, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran. s.akhond@neda.net.
authors.forename: Mohammadreza
authors.initials: M
authors.lastname: Mohammdi
authors.affiliation: Research Center for Behavioral Disorders and Substance Abuse, Hamadan University of Medical Sciences, Hamadan, Iran. s.akhond@neda.net.
authors.forename: Ali
authors.initials: A
authors.lastname: Ghaleiha
authors.affiliation: Psychiatric Research Centre, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran. s.akhond@neda.net.
authors.forename: Zahra
authors.initials: Z
authors.lastname: Keshavarzi
authors.affiliation: Psychiatric Research Centre, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran. s.akhond@neda.net.
authors.forename: Morteza
authors.initials: M
authors.lastname: Jafarnia
authors.affiliation: Department of Psychiatry, AJA University of Medical Sciences, Tehran, Iran. s.akhond@neda.net.
authors.forename: Rasool
authors.initials: R
authors.lastname: Keramatfar
authors.affiliation: Psychiatric Research Centre, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran. s.akhond@neda.net.
authors.forename: Rosa
authors.initials: R
authors.lastname: Alikhani
authors.affiliation: Psychiatric Research Centre, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran. s.akhond@neda.net.
authors.forename: Abolfazl
authors.initials: A
authors.lastname: Ehyaii
authors.affiliation: Psychiatric Research Centre, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran. s.akhond@neda.net.
authors.forename: Shahin
authors.initials: S
authors.lastname: Akhondzadeh
mesh_terms: D000328:Adult; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy*; D016642:Bupropion / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D016896:Treatment Outcome
chemical_list: D016642:Bupropion